Alps Group Inc has officially launched its Pharmaco-Interaction (PCI) laboratory unit, a significant expansion of its MyGenome subsidiary. This new unit will debut with CYP450 inhibitory IC50 testing as its first commercial service offering. The launch is a strategic move to enhance drug interaction safety in the health services sector, which is increasingly vital for both consumers and pharmaceutical companies.

Founded as a biotechnology platform, Alps Group Inc is headquartered in Kuala Lumpur, Malaysia. The company operates under the SIC classification of 8000, which pertains to health services. It trades on the Nasdaq under the ticker ALPS and also on the OTC market as ALPWF. The company has filed several recent reports, including a 6-K on November 12, 2026, detailing this latest development.

The SEC filing highlights that the PCI unit will focus on CYP450 inhibitory IC50 testing across seven major enzyme isoforms. This testing is crucial as these enzymes are responsible for metabolizing approximately 90% of marketed clinical drugs. The service will cater to herbal and supplement manufacturers, pharmaceutical companies, and research institutions, addressing a significant gap in the market for accredited CYP inhibition testing.

This development may significantly impact various stakeholders, including pharmaceutical companies and research institutions, who will now have access to advanced testing services that comply with FDA and EMA guidelines. The launch of the PCI unit is expected to enhance consumer confidence in drug safety and efficacy.

Looking ahead, Alps Group Inc may continue to expand its laboratory services portfolio, as indicated by the recent filings. However, the filing does not specify what further actions or developments will follow this launch.